866-997-4948(US-Canada Toll Free)

Pharmaceuticals North America (NAFTA) Industry Guide 2017

Published By :

MarketLine

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 80 Pages

Pharmaceuticals North America (NAFTA) Industry Guide 2017

Summary

The NAFTA Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the NAFTA pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

Key Highlights

- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The pharmaceuticals industry within the NAFTA countries had a total market value of $416.8 billion in 2016.The Mexico was the fastest growing country, with a CAGR of 10.2% over the 2012-16 period.
- Within the pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of $377.0 billion in 2016. This was followed by Mexico and Canada, with a value of $19.9 and $19.9 billion, respectively.
- The US is expected to lead the pharmaceuticals industry in the NAFTA bloc, with a value of $530.8 billion in 2021, followed by Canada and Mexico with expected values of $27.7 and $25.6 billion, respectively.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA pharmaceuticals market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA pharmaceuticals market
- Leading company profiles reveal details of key pharmaceuticals market players NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA pharmaceuticals market with five year forecasts
- Compares data from the US, Canada and Mexico, alongside individual chapters on each country

Reasons to buy

- What was the size of the NAFTA pharmaceuticals market by value in 2016?
- What will be the size of the NAFTA pharmaceuticals market in 2021?
- What factors are affecting the strength of competition in the NAFTA pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitors in the NAFTA pharmaceuticals market?
Table of Contents
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
NAFTA Pharmaceuticals
Industry Outlook
Pharmaceuticals in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Mexico
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in The United States
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine

List of Tables
Table 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2012-21
Table 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2012-16
Table 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2016-21
Table 4: Canada pharmaceuticals market value: $ billion, 201216
Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2016
Table 6: Canada pharmaceuticals market share: % share, by value, 2016
Table 7: Canada pharmaceuticals market value forecast: $ billion, 201621
Table 8: Canada size of population (million), 201216
Table 9: Canada gdp (constant 2005 prices, $ billion), 201216
Table 10: Canada gdp (current prices, $ billion), 201216
Table 11: Canada inflation, 201216
Table 12: Canada consumer price index (absolute), 201216
Table 13: Canada exchange rate, 201216
Table 14: Mexico pharmaceuticals market value: $ billion, 201216
Table 15: Mexico pharmaceuticals market geography segmentation: $ billion, 2016
Table 16: Mexico pharmaceuticals market share: % share, by value, 2016
Table 17: Mexico pharmaceuticals market value forecast: $ billion, 201621
Table 18: Mexico size of population (million), 201216
Table 19: Mexico gdp (constant 2005 prices, $ billion), 201216
Table 20: Mexico gdp (current prices, $ billion), 201216
Table 21: Mexico inflation, 201216
Table 22: Mexico consumer price index (absolute), 201216
Table 23: Mexico exchange rate, 201216
Table 24: United States pharmaceuticals market value: $ billion, 201216
Table 25: United States pharmaceuticals market geography segmentation: $ billion, 2016
Table 26: United States pharmaceuticals market share: % share, by value, 2016
Table 27: United States pharmaceuticals market value forecast: $ billion, 201621
Table 28: United States size of population (million), 201216
Table 29: United States gdp (constant 2005 prices, $ billion), 201216
Table 30: United States gdp (current prices, $ billion), 201216
Table 31: United States inflation, 201216
Table 32: United States consumer price index (absolute), 201216
Table 33: United States exchange rate, 201215
Table 34: Apotex, Inc.: key facts
Table 35: Johnson & Johnson: key facts
Table 36: Johnson & Johnson: key financials ($)
Table 37: Johnson & Johnson: key financial ratios
Table 38: Merck & Co., Inc.: key facts
Table 39: Merck & Co., Inc.: key financials ($)
Table 40: Merck & Co., Inc.: key financial ratios
Table 41: Pfizer Inc.: key facts
Table 42: Pfizer Inc.: key financials ($)
Table 43: Pfizer Inc.: key financial ratios
Table 44: Bayer AG: key facts
Table 45: Bayer AG: key financials ($)
Table 46: Bayer AG: key financials ()
Table 47: Bayer AG: key financial ratios
Table 48: Novartis AG: key facts
Table 49: Novartis AG: key financials ($)
Table 50: Novartis AG: key financial ratios
Table 51: AstraZeneca PLC: key facts
Table 52: AstraZeneca PLC: key financials ($)
Table 53: AstraZeneca PLC: key financial ratios

List of Figures
Figure 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2012-21
Figure 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2012-16
Figure 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2016-21
Figure 4: Canada pharmaceuticals market value: $ billion, 201216
Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 6: Canada pharmaceuticals market share: % share, by value, 2016
Figure 7: Canada pharmaceuticals market value forecast: $ billion, 201621
Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2016
Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2016
Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2016
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2016
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2016
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2016
Figure 14: Mexico pharmaceuticals market value: $ billion, 201216
Figure 15: Mexico pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 16: Mexico pharmaceuticals market share: % share, by value, 2016
Figure 17: Mexico pharmaceuticals market value forecast: $ billion, 201621
Figure 18: Forces driving competition in the pharmaceuticals market in Mexico, 2016
Figure 19: Drivers of buyer power in the pharmaceuticals market in Mexico, 2016
Figure 20: Drivers of supplier power in the pharmaceuticals market in Mexico, 2016
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2016
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2016
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2016
Figure 24: United States pharmaceuticals market value: $ billion, 201216
Figure 25: United States pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 26: United States pharmaceuticals market share: % share, by value, 2016
Figure 27: United States pharmaceuticals market value forecast: $ billion, 201621
Figure 28: Forces driving competition in the pharmaceuticals market in the United States, 2016
Figure 29: Drivers of buyer power in the pharmaceuticals market in the United States, 2016
Figure 30: Drivers of supplier power in the pharmaceuticals market in the United States, 2016
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2016
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2016
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2016
Figure 34: Johnson & Johnson: revenues & profitability
Figure 35: Johnson & Johnson: assets & liabilities
Figure 36: Merck & Co., Inc.: revenues & profitability
Figure 37: Merck & Co., Inc.: assets & liabilities
Figure 38: Pfizer Inc.: revenues & profitability
Figure 39: Pfizer Inc.: assets & liabilities
Figure 40: Bayer AG: revenues & profitability
Figure 41: Bayer AG: assets & liabilities
Figure 42: Novartis AG: revenues & profitability
Figure 43: Novartis AG: assets & liabilities
Figure 44: AstraZeneca PLC: revenues & profitability
Figure 45: AstraZeneca PLC: assets & liabilities

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *